[ad_1]
With robust three-month efficiency and vital upside potential, Compass Therapeutics, Inc. (NASDAQ:CMPX) secures a spot on our checklist of the 12 scorching penny shares to put money into proper now.
A health care provider in a lab coat holding a healthcare resolution of their arms.
On November 10, 2025, H.C. Wainwright’s Joseph Pantginis reiterated a “Purchase” score on Compass Therapeutics, Inc. (NASDAQ:CMPX) with a $24 worth goal. The corporate’s advancing pipeline, marked by the preclinical progress of CTX-10726, gained the analyst’s confidence, who was notably impressed with the bispecific antibody’s substantial potential. At SITC 2025, the drug demonstrated high-affinity goal engagement and strong anti-tumor exercise. The analyst additionally cited the molecule’s aggressive edge over brokers comparable to ivonescimab and bevacizumab, reinforcing optimism as its deliberate Part 1 trial in 2026 comes nearer.
In the meantime, Compass Therapeutics, Inc. (NASDAQ:CMPX) reported Q3 2025 outcomes on November 5. The money stability reached $220 million by the tip of Q3, which is able to help operations via 2028. G&A bills recorded a considerable enhance, rising from $8.6 million in Q3 2024 to $12.8 million. Administration additionally reiterated its expectations to ship total survival (OS) and progression-free survival (PFS) knowledge for tovecimig in late Q1 2026. This might probably help the corporate’s first BLA submitting within the second half of 2026. On the similar time, Compass reported encouraging ends in the Part 1 examine of CTX-8371. The corporate recorded a internet lack of $14.3 million, or $0.08 per share, for the quarter.
Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage oncology firm, develops antibody-based therapies concentrating on angiogenesis, immune activation, and tumor evasion pathways.
Whereas we acknowledge the potential of CMPX as an funding, we consider sure AI shares supply better upside potential and carry much less draw back threat. In case you’re searching for an especially undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring development, see our free report on the greatest short-term AI inventory.
READ NEXT: 10 Greatest Small-Cap Biotech Shares to Purchase In keeping with Analysts and 11 Neglected Tech Shares to Make investments In.
Disclosure: None.
[ad_2]
